Astellas Pharma US, Inc. Satellite Symposium
COMBINATION TREATMENT FOR PATIENTS WITH OAB
Agenda
| Start |
End |
Subject |
Speaker |
| 17:45 |
18:05 |
Introduction |
David R. Staskin |
| 18:05 |
18:35 |
Panel Discussion |
David R. Staskin, Peter K. Sand, & Scott A. MacDiarmid |
| 18:35 |
18:45 |
Audience Questions and Answers |
All |
Programme Objectives
• Review the epidemiology of overactive bladder (OAB)
• Discuss the American Urological Association (AUA) treatment guidelines for OAB and explore the unmet needs of some patient populations
• Review clinical data of a new treatment approach for OAB
• Discuss the new treatment options for patients with OAB
Please note this session is not included in main Meeting CME/CPD credit.
The views expressed in this Satellite Symposium are those of the company and speakers and not necessarily those of the International Continence Society.